International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.

Slični predmeti

• Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
  od: Sharma, A, i dr.
  Izdano: (2016)
• Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
  od: Califf, R, i dr.
  Izdano: (2008)
• Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
  od: Preiss, D, i dr.
  Izdano: (2012)
• People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
  od: Califf, R, i dr.
  Izdano: (2003)
• Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
  od: Yates, T, i dr.
  Izdano: (2014)